224 related articles for article (PubMed ID: 16172484)
41. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
42. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis.
Huet E; Hadji C; Hulin A; Botterel F; Bretagne S; Lévy Y
AIDS; 2008 Sep; 22(14):1885-6. PubMed ID: 18753868
[No Abstract] [Full Text] [Related]
44. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil.
Karimi K; Wheat LJ; Connolly P; Cloud G; Hajjeh R; Wheat E; Alves K; Lacaz Cd Cda S; Keath E
J Infect Dis; 2002 Dec; 186(11):1655-60. PubMed ID: 12447743
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study.
Mildvan D; Creagh T; Leitz G;
Curr Med Res Opin; 2007 Feb; 23(2):343-55. PubMed ID: 17288689
[TBL] [Abstract][Full Text] [Related]
46. [Clinical impacts of highly active antiretroviral therapy on patients of hemophilia combined with acquired immunodeficiency syndrome: 6-year follow-up of 39 cases].
Dai ZS; Zhang XX; Wang JR; Zhang YJ; Sun HQ; Lu HZ
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):872-5. PubMed ID: 19671284
[TBL] [Abstract][Full Text] [Related]
47. Long-term study of intraocular pressure changes in patients with human immunodeficiency virus treated with highly active antiretroviral therapy.
Kozak I; LaBree L; Azen SP; Cheng L; Reagan NL; Freeman WR
Ophthalmology; 2006 Mar; 113(3):451-5. PubMed ID: 16513459
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
49. Diffuse ulcerations due to disseminated histoplasmosis in a patient with HIV.
Scheinfeld N
J Drugs Dermatol; 2003 Apr; 2(2):189-91. PubMed ID: 12852372
[TBL] [Abstract][Full Text] [Related]
50. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy.
Gaardbo JC; Nielsen SD; Vedel SJ; Ersbøll AK; Harritshøj L; Ryder LP; Nielsen JO; Kolte L
Clin Exp Immunol; 2008 Oct; 154(1):80-6. PubMed ID: 18821942
[TBL] [Abstract][Full Text] [Related]
51. Case of disseminated histoplasmosis in a HIV-infected patient revealed by nasal involvement with maxillary osteolysis.
Lehur AC; Zielinski M; Pluvy J; Grégoire V; Diamantis S; Bleibtreu A; Rioux C; Picard A; Vallois D
BMC Infect Dis; 2017 May; 17(1):328. PubMed ID: 28476105
[TBL] [Abstract][Full Text] [Related]
52. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
53. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
54. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
[TBL] [Abstract][Full Text] [Related]
55. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
[TBL] [Abstract][Full Text] [Related]
56. Optimizing the care of minority patients with HIV/AIDS.
Stone VE
Clin Infect Dis; 2004 Feb; 38(3):400-4. PubMed ID: 14727211
[TBL] [Abstract][Full Text] [Related]
57. Itraconazole in human histoplasmosis.
Negroni R; Robles AM; Arechavala A; Taborda A
Mycoses; 1989 Mar; 32(3):123-30. PubMed ID: 2543924
[TBL] [Abstract][Full Text] [Related]
58. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors.
Couppié P; Sobesky M; Aznar C; Bichat S; Clyti E; Bissuel F; El Guedj M; Alvarez F; Demar M; Louvel D; Pradinaud R; Carme B
Clin Infect Dis; 2004 Jan; 38(1):134-8. PubMed ID: 14679459
[TBL] [Abstract][Full Text] [Related]
59. Disseminated histoplasmosis in HIV-infected patients: determinants of relapse and mortality in a north-eastern area of Brazil.
Damasceno LS; Ramos AN; Alencar CH; Gonçalves MV; de Mesquita JR; Soares AT; Coutinho AG; Dantas CC; Leitão Tdo M
Mycoses; 2014 Jul; 57(7):406-13. PubMed ID: 24612078
[TBL] [Abstract][Full Text] [Related]
60. [Efficacy of highly active antiretroviral therapy for childhood acquired immunodeficiency syndrome].
Hao JL; Wang BJ; Baptiste J
Zhongguo Dang Dai Er Ke Za Zhi; 2010 Nov; 12(11):874-6. PubMed ID: 21083982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
